Agios rises in advance of AG-120 presentation

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) gained $16.09 (25%) to $80.94 on Tuesday after it said it would present results from a Phase I study of AG-120 in patients with isocitrate dehydrogenase 1 (IDH1)-mutant positive advanced solid tumors at a plenary session of the AACR-NCI-EORTC meeting in Boston. An abstract for the study is to be posted Nov. 8; it will be featured in the conference's press program later that day.

In a note issued post-market Monday, Jefferies analyst Brian Abrahams wrote that "the fact that the abstract is withheld for publication in the conference's press program and will be presented as a plenary suggests encouraging results." ...